News
VINC
0.5674
-5.84%
-0.0352
Vincerx Pharma Inc <VINC.OQ> expected to post a loss of $3.40 a share - Earnings Preview
Reuters · 2d ago
Weekly Report: what happened at VINC last week (0317-0321)?
Weekly Report · 3d ago
BUZZ-U.S. STOCKS ON THE MOVE-Aditxt, Natgas companies, DocuSign
Reuters · 03/18 17:47
BUZZ-Vincerx Pharma soars on QumulusAI merger deal
Reuters · 03/18 14:14
Vincerx Pharma Shares Soar on Proposed Merger with Global Digital Holdings
Dow Jones · 03/18 13:34
VINCERX PHARMA : AS OF FEB 28, 2025, HAD ABOUT$3.9 MLN IN CASH AND ANTICIPATES ITS CASH RUNWAY WILL EXTEND INTO LATE Q2 2025
Reuters · 03/18 13:13
Vincerx Pharma Enters Non-Binding LOI With QumulusAI For Reverse Merger; QumulusAI To Own 95% Of Combined Entity Valued At $285M, Vincerx At $15M; QumulusAI Or Its Designees Will Invest Up To $1.5M In The Equity Of Vincerx Prior To Closing
Benzinga · 03/18 12:55
VINCERX PHARMA INC - QUMULUSAI TO INVEST UP TO $1.5 MILLION IN VINCERX EQUITY
Reuters · 03/18 12:52
Press Release: Vincerx Pharma Announces -2-
Dow Jones · 03/18 12:52
Press Release: Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI
Dow Jones · 03/18 12:52
Weekly Report: what happened at VINC last week (0310-0314)?
Weekly Report · 03/17 11:29
Weekly Report: what happened at VINC last week (0303-0307)?
Weekly Report · 03/10 11:31
Weekly Report: what happened at VINC last week (0224-0228)?
Weekly Report · 03/03 11:30
US Stocks Likely To Open Higher As Wall Street Watches TruTariff Talks: 'March, April, May Tend To Be Solid Months In Post-Election Years,' Says Expert
Benzinga · 03/03 10:55
Vincerx Pharma Plunges After Scrapping Reverse Merger With Oqory And Vivaso
NASDAQ · 03/03 10:10
Vincerx Pharma Terminates Reverse Merger Deal With Oqory
Dow Jones · 02/28 21:55
Vincerx Pharma Inc trading resumes
TipRanks · 02/28 21:40
Vincerx Pharma Explores Strategic Alternatives Post Merger Termination
TipRanks · 02/28 21:32
Vincerx Pharma terminates reverse merger term sheet and evaluates strategic alternatives
Seeking Alpha · 02/28 21:26
*Vincerx Pharma Sees Funding Sufficient Through Late 2Q >VINC
Dow Jones · 02/28 21:07
More
Webull provides a variety of real-time VINC stock news. You can receive the latest news about Vincerx Pharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About VINC
More
Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing differentiated and novel therapies to address the unmet medical needs of patients with cancer. It has a next generation bioconjugation platform, called VersAptx. The VersAptx platform is a versatile and adaptable, next generation bioconjugation platform. Its product candidates include VIP943 (CD123-KSPi), VIP924 (CXCR5-KSPi), VIP236, and Enitociclib (P-TEFb/CDK9 inhibitor). VIP943 is a potential anti-CD123 ADC created with its VersAptx Platform. It consists of an anti-CD123 antibody, a novel legumain-cleavable linker, and a KSPi payload enhanced with its CellTrapper technology. Enitociclib is a selective CDK9 inhibitor. Enitociclib effectively blocks P-TEFb-mediated activation of RNA polymerase II, preventing transcription of MCL1 and MYC, proteins associated with poor prognosis in various types of cancer.